Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Pharming - 1 juli 2014

Aandeel Pharming Group NL0010391025

Laatste koers (eur) Verschil Volume
0,890   +0,007   (+0,79%) Dagrange 0,885 - 0,890 25.979   Gem. (3M) 5,4M

Pharming - 1 juli 2014

Volgen
476 Posts
Pagina: «« 1 ... 19 20 21 22 23 24 »» | Laatste | Omlaag ↓
  8. [verwijderd] 1 juli 2014 19:38
    quote:

    Sentiment schreef op 1 juli 2014 17:54:

    [...]nee hoor, dat zou bij de grote beleggers allang uitgelekt zijn en die zouden dan juist verkocht hebben, het tegenovergestelde is vandaag gebeurd
    Misschien heb je gelijk, helaas was het het afgelopen jaar, naar mijn mening 3x het geval dat dit zo ging!!
  14. forum rang 10 voda 1 juli 2014 20:20
    quote:

    bik schreef op 1 juli 2014 20:12:

    Wacht en huiver,mien jong>........
    Laatste koersnieuws!!

    Buy, buy, buy, koersdoel $3

    PHARM: Management Meeting and Approval
    in Israel; Target Upped to $3
    A discussion with management indicated a flurry of background activities
    ahead of the April PDUFA for Ruconest. Additionally, Pharming announced
    that partner MegaPharm received marketing authorization and reimbursement
    approval for Ruconest in Israel. All eyes remain on the April 2014 PDUFA date
    for Ruconest in the U.S. Reiterate Buy and raising price target to $3 from $2.
    Event
    We met with management of Pharming to discuss background activities ahead
    of the April PDUFA for Ruconest in the U.S. Recall that U.S. partner Santarus
    (SNTS-Neutral) was recently acquired by Salix (SLXP-Buy) and there were no
    change of control issues regarding the partnership with Pharming. Additionally,
    Pharming's partner, privately-owned MegaPharm Ltd., received approval and
    full reimbursement for Ruconest in Israel. MegaPharm will buy a commercial
    supply of Ruconest from PHARM at a price based on percentage of net sales
    and anticipates launching the drug 1Q in Israel.
    Impact: We believe Pharming is well positioned for 2014 wiith what we
    consider to be the de-risked April PDUFA for Ruconest coming up soon
    (positive Phase III under SPA). Overall we believe two major factors (of several)
    will help propel Pharming forward this year; 1) Shire acquisition of ViroPharma
    for $4.2 billion (Ruconest represents a pure and safer threat to Cinryze) and 2)
    Salix' acquisition of Santarus (Pharming's U.S. partner). Ruconest is approved
    ex-U.S. for the treatment of acute angioedema attacks in patients with
    hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. Recall
    that PHARM has also partnered with Shangai Institute of Pharmaceutical
    Industry (SIPI), a division of Sinopharm, for commercialization of Ruconest in
    China. We believe that the drug is poised to take over a significant share of
    the HAE market, given its low COGS allowing for competitive pricing, safety,
    convenience, and strong efficacy. Ruconest benefits from a benign safety
    profile, with no thromboembolic events seen to date, compared to plasma
    derived Cinryze and Berinert with an incidence of ~3.4% rate of thrombosis
    events. This may be attributable to the plasma derived Cinryze and Berinert
    with ~20-25% impurities in their formulations.
    Action: We reiterate our Buy rating and are increasing our target to $3 from $2.
    The company's strategy to expand geographies through collaborations and to
    develop therapies for rare diseases will bear fruit over the long term, in our
    opinion. Given the pricing power of orphan drugs and the expanding markets
    in these indications due to better diagnoses, we believe that Pharming is wellpositioned
    for commercial success.

    VALUATION
    We reiterate our Buy rating and are increasing our target to $3 from $2. The primary changes to our valuation
    include:
    n Change in share count
    n Change in base year
    n Increase projected ex-U.S. peak sales from $15 million to $25 million for Ruconest
    n Increase projected U.S. peak sales from $200 million to $225 million.
    Our valuation of Pharming is based on our probability-weighted clinical net present value (NPV) valuation
    model. We believe this method is appropriate in capturing the value of the clinical stage pipeline. Factors that
    could impact the shares of Pharming reaching our price target are negative data readouts from ongoing clinical
    studies, any perceived or real delays in the commercial uptake of Rhucin/Ruconest as well as Pharming's
    ability to continue to fund its operations.
    RISKS
    · Regulatory Risk. FDA had issued a Refuse to File (RTF) letter to Pharming/Santarus’ BLA submitted in
    December 2010, outlining concerns that efficacy data for the proposed Rhucin dose of 50 U/kg relied on a
    small number of patients, and that the method used to assess the primary endpoint had not been prospectively
    defined. The companies engaged in discussions with the agency and are sponsoring an additional Phase III
    trial (conducted under SPA) to address the issues raised by the FDA. In November 2012 this Phase III study
    met its primary endpoint. While we believe risk was reduced for the program, there is still no guarantee that
    the FDA will approve the product or issue a Complete Response letter.
    · Financial Risk. Pharming is currently a non-profitable biotechnology company, and funding is continuously
    necessary to support operations and ongoing clinical studies. Should Pharming encounter problems in raising
    sufficient funds to continue its operations, the company’s valuation may be greatly impacted.
    · Partnering Risk. Pharming has attracted partnerships from SOBI and Santarus for Rhucin. Should it become
    unable to meet its agreement obligations or if clinical data fails to show safety and meaningful efficacy, the
    partnerships could be terminated. The company’s progress with the development of its candidate products
    may be delayed, and future commercial activity negatively impacted.
    · Demand and reimbursement risk. Rhucin is currently approved in Europe and developed in the U.S.
    for the treatment of HAE, a rare disease for which prevalence estimates vary greatly due to misdiagnosis
    and underdiagnosis. Failure to properly estimate market size may negatively impact Pharming’s valuation. In
    addition, Rhucin faces competition from 3 other drugs in the acute HAE setting. Pharming and its collaborators
    may have to undertake extensive efforts to educate physicians of the advantages of Rhucin over competitor
    products. Finally, given increased austerity measures imposed in Europe and pressure to reduce medical
    spending, Rhucin may see reimbursement pushback. However, we believe that Pharming is attempting to
    mitigate this risk having priced Ruconest in Europe at a competitive level, compared to alternative treatments

    Bron!

    roth2.bluematrix.com/sellside/EmailDo...

    Geintje natuurlijk Bik.

    Heb ik eindelijk eens dat rapport opengetrokken.
  17. [verwijderd] 1 juli 2014 20:27
    quote:

    tb alrac schreef op 1 juli 2014 20:22:

    [...]Pas maar op misschien weeg ik wel 175 kilo. Bump ik je bij de bbq zo het vuur in ;-)

    www.youtube.com/watch?v=ZWNJwSJh_WY
    Over vuur en vrouwen, op een mooie dag. Het rubber begaf het wel, daar werd de dame dan weer zwaar van...

    www.youtube.com/watch?v=l16IKnKVvo8
476 Posts
Pagina: «« 1 ... 19 20 21 22 23 24 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. Pharming heeft bijna 93% van Abliva in handen
  2. Pharming verklaart bod op Abliva onvoorwaardelijk
  3. Pharming stemt over nieuwe CEO
  4. Pharming presenteert nieuwe CEO
  5. Fundlogic verkoopt bijna geheel belang in Pharming
  6. Fundlogic flink groter in Pharming
  7. DWS meldt groter belang in Pharming
  8. Morgan Stanley groter in Pharming
  9. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  10. RBC verhoogt koersdoel Pharming fors